Insider · CIK 0001824721

Beigelman Leonid

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001824721

Forms 4 and 5

Insider transactions

23 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2023-03-15	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President	AAward	+170K sh	—	—	169,500
2022-07-07	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President	AAward	+113K sh	—	—	113,000
2022-02-04	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President	AAward	+227K sh	—	—	226,800
2022-02-04	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President	AAward	+56.7K sh	—	—	56,700
2020-12-01	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President	AAward	+300K sh	—	—	300,000
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+164K sh	—	—	163,842
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+13.6K sh	—	—	13,559
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+13.6K sh	—	—	13,559
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+50.8K sh	—	—	214,623
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+3,359 sh	—	—	16,918
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+3,359 sh	—	—	16,918
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+21.7K sh	—	—	236,347
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+1,437 sh	—	—	18,355
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President	CConversion	+1,437 sh	—	—	18,355
2020-10-20	ALGSAligos Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, President	CConversion	−164K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, President	CConversion	−13.6K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, President	CConversion	−13.6K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, President	CConversion	−50.8K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, President	CConversion	−3,359 sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, President	CConversion	−3,359 sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-2 Preferred StockC Conversion	Director, President	CConversion	−21.7K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-2 Preferred StockC Conversion	Director, President	CConversion	−1,437 sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-2 Preferred StockC Conversion	Director, President	CConversion	−1,437 sh	—	—	0

Recent filings

Accepted (ET)
Mar 174
Beigelman Leonid0001567619-23-005252
SEC(opens sec.gov)
Jul 114
Beigelman Leonid0001567619-22-013867
SEC(opens sec.gov)
Feb 84
Beigelman Leonid0001567619-22-002889
SEC(opens sec.gov)
Dec 34
Beigelman Leonid0001567619-20-020622
SEC(opens sec.gov)
Oct 204
Beigelman Leonid0001567619-20-018000
SEC(opens sec.gov)

Companies

Aligos Therapeutics, Inc.Director, PresidentALGS

Address

C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR

SOUTH SAN FRANCISCO, CA, 94080